-

About

I am a medical oncologist with a special interest in colorectal cancer.

My research is aimed at understanding the features of colorectal cancer that predict how a patient will experience the disease, such as whether they will respond to therapy and whether they are at risk of recurrence following surgery.

I am also exploring whether a simple blood test could be used for the early detection of cancer, diagnosing tumours before they spread, when the chance of cure is high.

Publications

Selected publications from Prof Jeanne Tie

Michael M, Wong R, Gill S, Strickland AH, Pavlakis N, Shapiro JD, Link E, Farrell M, Ngan SY, Tie J, Heriot AG, Goldstein D, Mitchell C, Roth S, Wilson K, Mui M, Ramsay RG, Segelov E. The Ave-Rec trial: Phase II trial of PDL1/PD-1 blockade with Avelumab post Chemoradiotherapy for locally advanced resectable T3B-4/N1-2 Rectal cancer.Clinical Cancer Research. 2025;:10.1158/1078-0432.ccr-25-0705

Burge ME, Espinoza D, Sjoquist KM, Siu DH, Mercieca-Bebber R, Chantrill LA, Karapetis CS, Steer CB, Yip S, Cuff J, Winata S, Tie J, Thaker DA, Srivastav R, Abdi E, Strickland A, Segelov E, Francesconi A, Price T, Ladwa R, Joubert W, Tebbutt NC. AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG). Clinical Colorectal Cancer. 2025;24(2):10.1016/j.clcc.2024.11.003

Tie J, Wang Y, Loree JM, Cohen JD, Espinosa D, Wong R, Price TJ, Tebbutt NC, Lee M, Burge ME, Harris SJ, Lee B, Lynam JF, O’Callaghan CJ, Breadner DA, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.3503

McLachlan S-A, Mostafa R, Sharpe L, Burge ME, Day F, Blum RH, Campbell R, Lynam JF, Lee B, Singh MS, Lee M, Chantrill LA, Lundy J, Wong ZW, Wong R, Joshi S, Saqib A, Karikios DJ, Gibbs P, Tie J. Circulating tumor DNA (ctDNA) analysis guiding adjuvant therapy in patients (pts) with colorectal cancer (CRC): Impact on fear of cancer recurrence (FCR).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.11125

Chantrill LA, Samra JS, Tebbutt NC, Nikfarjam M, Reid D, Brungs D, Jaber M, Tie J, Mendis SR, Hong W, Cavicchiolo T, Cuff J, Hayes SJ, Christophersen LC, Roesner M, Maloney S. Neo-adjuvant chemo-immunotherapy in pancreatic cancer: Results of the Australasian Gastrointestinal Trials Group (AGITG) NEO-IMPACT pilot trial.Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.4189

Tie J, Melian M, Ruiz-Casado A, Wyrwicz L, Wysocki PJ, Stuebs P, Aranda E, Salas N, Elez E, Curigliano G, Radecka B, Parseghian C, Takacs I, Heinemann V, Vandal G, Huniti N, Vidal Barrul J. Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib (A), in combination with encorafenib (E) and cetuximab (C) in patients (pts) with previously treated BRAF V600E mutantmetastatic colorectal cancer (mCRC).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.3551

Shi Q, Chang GJ, Pederson LD, Asare EA, Jin Z, Cohen R, Meyerhardt JA, Andre T, Tie J, Dixon JG, Palis BE, Ballman KV, Yothers G, Ma Z, Alberts SR, Shi C, Washington MK, Taieb J, Steele S, Goldberg RM. Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCCEP).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.3520

Sanderson E, Gibbs P, Tie J. The emerging clinical utility of ctDNA to guide adjuvant treatment in cancer. The Lancet Regional Health – Western Pacific. 2025;59:10.1016/j.lanwpc.2025.101595

Tie J, Wang Y, Lo SN, Lahouel K, Cohen JD, Wong R, Shapiro JD, Harris SJ, Khattak A, Burge ME, Lee M, Harris M, McLachlan S-A, Horvath L, Karapetis C, Shannon J, Singh M, Yip D, Ananda S, Underhill C, Ptak J, Silliman N, Dobbyn L, Popoli M, Papadopoulos N, Tomasetti C, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nature Medicine. 2025;31(5):10.1038/s41591-025-03579-w

Kim GY, Tie J, Gibbs P. Letter to the Editor: Are We Asking the Right Question for New Biomarkers – “Ready for Prime Time” Versus Demonstrated Clinical Utility?. Journal of the National Comprehensive Cancer Network. 2025;23(5):10.6004/jnccn.2025.7037

Interested in supporting our research?

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Contact our friendly team to find out how you can help.